Abstract
Background: Nectin-4 has recently emerged as a highly valuable therapeutic target. This is due to its overexpression in epithelial cancers, including ovarian, breast, colorectal, lung, and pancreatic, while exhibiting limited expression in normal adult tissue. This overexpression is functionally significant for tumor progression, making Nectin-4 an ideal target for potential cancer therapeutics. Using a high-throughput flow cytometry-based antibody screening procedure, wherein antibody binding to native cell-expressed Nectin-4 is assessed concomitantly with off-target binding, multiple antibodies were identified.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
